Credit: Pixabay/CC0 Public Domain Facemasks will no longer be compulsory outdoors in Italy, one of the countries in Europe worst hit by the coronavirus, from June 28, the health ministry said Monday. The lifting of the mask requirement would come into effect in regions labelled “white” under Italy’s classification system…
Andy Grammer: Baby No. 3 Will Be a ‘Tough Sell’ for Wife
Nah, nah, honey, she’s good! Andy Grammer sat down with Us Weekly and revealed that his wife, Aijia Lise Grammer, is not totally on board with having baby No. 3. Watch the latest episode of Moms Like Us above to hear what the multi-platinum recording artist, 37, had to say about their plans for…
No benefit to FFR-guided PCI in STEMI patients with multi-vessel disease
In patients who had a coronary stent inserted after experiencing the most severe type of heart attack, the use of a technique that measures blood flow and pressure through a partially blocked artery to determine if a second stenting procedure is needed did not improve outcomes and was more costly…
No, vaccine side effects don’t tell you how well your immune system will protect you from COVID-19
If someone gets a headache or feels a bit under the weather after receiving a COVID-19 vaccine, it’s become common to hear them say something like “Oh, it just means my immune system is really working hard.” On the flip side, when people don’t notice any side effects, they sometimes…
AstraZeneca says vaccine 80% effective for elderly, no blood clot risk
AstraZeneca’s Covid-19 vaccine is 80 percent effective at preventing the disease in the elderly and does not increase the risk of blood clots, the biotech firm said Monday, following its US phase III efficiency trials. It was 79 percent effective at preventing symptomatic Covid-19 in the overall population and 100…
Imagine having your period and no money for pads or tampons. Would you still go to school?
The New South Wales Education Department said last week said it would trial a program to hand out free pads and tampons in schools. Department secretary Mark Scott said: “We are developing work on a pilot program around this and details will be emerging on that shortly.” In a recent…
‘No COVID-19 is good COVID-19’: Variants spur scientists to study, mitigate strain outbreaks
West Virginia University scientists knew it was coming. When health officials confirmed the first three cases of a COVID-19 variant in West Virginia late Friday (Feb. 19), they were not surprised. In fact, WVU researchers had, in recent weeks, already formed a partnership with colleagues at Marshall University and the…
No importa cuál te toque. Cuando tengas oportunidad, vacúnate contra covid
A la hora de vacunarse contra covid-19 no hay que ser quisquilloso. Los expertos afirman que debes ponerte la primera vacuna autorizada que te ofrezcan. La vacuna anti covid más reciente, de Johnson & Johnson, es probablemente un poco menos eficaz para prevenir la enfermedad que las dos vacunas que…
Low-carb, no sugar, no fat: the fad diets popular in the 20th century
Fad diets certainly aren’t a 21st-century obsession. In fact, they were also a popular way for people throughout the 20th century to slim down and improve their health. Though much has changed since then—including what we know about dieting and weight loss—many of the popular fad diets we follow today…
Certain CBD oils no better than pure CBD at inhibiting certain cancer cell lines
Cannabidiol (CBD) oils are equally or less effective at inhibiting the growth of certain cancer cells compared to pure CBD, according to Penn State College of Medicine researchers. The results of their recent study indicate that future research into the clinical applications of cannabinoids should include an analysis of whether…
Fostamatinib in chronic immune thrombocytopenia: No comparison—added benefit not proven
Fostamatinib is approved for the treatment of chronic immune thrombocytopenia in adults who are refractory to other treatments (in particular to treatment with corticosteroids). The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether fostamatinib offers an added benefit for these patients…